We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 315

Tesla’s patent pledge: is it enough?

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • July 23 2014

Free use of patented technology? Caveat emptor. In a June 12, 2014 blog post titled, "All Our Patent Are Belong To You", Elon Musk, co-founder and

Doctrine of bona fide purchaser for value without notice applies to patent rights

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • February 6 2012

This case involves a dispute over who owned certain patent rights

Reply affidavits allowed when new documents introduced in responding evidence

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • January 9 2014

In this case, there is a partial reversal of evidence. Apotex brought a motion for leave to file reply evidence. Allergan did not oppose parts of the

Impeachment action in respect of expired patent allowed to continue

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • December 17 2012

Apotex commenced an impeachment action in respect of two patents. Warner-Lambert brought a motion seeking to dismiss the action as it related to one patent

Claim to disgorgement of profits denied by Ontario Court of Appeal

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • September 18 2013

Apotex appealed in the Ontario Court of Appeal from a partial summary judgment that dismissed its unjust enrichment claim for the disgorgement of the

Intellectual property weekly abstract bulletin

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • October 2 2013

The Federal Court of Appeal (FCA) recently upheld the decision of the Trial Judge, holding that one claim of the patent at issue was valid and

Court appears to contemplate more than one collection of damages possible after NOC proceeding is dismissed

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • November 27 2013

In this action, Apotex is suing for additional damages, including treble damages and an accounting of Sanofi's profits, pursuant to inter alia, the

Leave to appeal dismissed

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • November 7 2012

In the Matter of Sandoz Canada Inc. Week of November 5, 2012 The Supreme Court has dismissed Teva’s application for leave to appeal

Merck leave to appeal to SCC dismissed

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • June 18 2012

The Supreme Court of Canada dismissed Merck’s application for leave to appeal, with costs to Apotex

Ontario Court dismisses generic claims for unjust enrichment in s. 8 proceeding

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • January 30 2013

Apotex sued Abbott and Takeda for damages pursuant to s. 8 of the NOC Regulations. As part of the claim, Apotex claimed disgorgement of profits